• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconWegovy

Wegovy

Page 2 of 7
A woman injects herself with medication.
Health
Ozempic, Wegovy maker calls out Hims & Hers Super Bowl ad: ‘Check before you inject’
By Lindsey LeakeFebruary 11, 2025
Novo Nordisk President and CEO Lars Fruergaard Jorgensen testifies before the Senate Health, Education, Labor, and Pensions Committee in the Dirksen Senate Office Building on Capitol Hill on September 24, 2024 in Washington, DC. The committee heard testimony from Jorgensen about the price of popular pharmaceuticals made by Novo Nordisk that help treat diabetes and obesity, including Wegovy and Ozempic.
Leadership
As U.S. firms scrap diversity targets, the CEO behind Ozempic and Wegovy took a pay cut for missing them
By Ryan HoggFebruary 5, 2025
Karsten Munk Knudsen, chief financial officer of Novo Nordisk A/S, at the company's headquarters in Bagsvaerd, Denmark, on Tuesday, Nov. 26, 2024.
Health
As growth slows, CFO says Novo Nordisk is prepping for the next generation of weight loss drugs
By Ryan HoggFebruary 5, 2025
A person stands on a scale.
Health
Hims & Hers Super Bowl ad slams pricey pharma industry—and fumbles FDA warnings on compounded GLP-1 drugs
By Lindsey LeakeFebruary 3, 2025
Ozempic and Wegovy medications side by side
Health
Ozempic and Wegovy surge to national approval with most U.S. adults considering it ‘a good thing’ to treat obesity
By The Associated Press, Kenya Hunter and Linley SandersJanuary 31, 2025
The increase in online searches for obesity management drugs in recent years correlated to a surge in dispensed prescriptions, according to a new study from the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease.
Health
Online searches predicted the surge in prescriptions of weight-loss drugs like Wegovy and Zepbound, study says. Here’s what could happen next
By Lindsey LeakeJanuary 29, 2025
A person, with only the midsection visible, injects Wegovy under the skin of their stomach.
Finance
Novo Nordisk stock surges 7% after Ozempic maker’s latest weight-loss drug shows promise
By Greg McKennaJanuary 24, 2025
Eli Lilly & Co., the Fortune 500 pharma firm that manufactures weight-loss injection Zepbound (tirzepatide), has a comparable oral medication in the works that could be approved by the FDA as early as 2026, CEO Dave Ricks told Bloomberg TV on Jan. 13, 2025.
Health
Hate needles? Lilly’s weight-loss pill could get FDA approval next year, CEO says
By Lindsey LeakeJanuary 21, 2025
Elon Musk admits he takes an Ozempic-like weight-loss drug that RFK Jr. wants to restrict
Health
Elon Musk admits he takes an Ozempic-like weight-loss drug that RFK Jr. wants to restrict
By Alexa MikhailDecember 27, 2024
Novo Nordisk advertising flags and logo on facade, Danish pharmaceutical healthcare giant Novo Nordisk AS, production innovative drugs, obesity treatment Ozempic, Mainz, Germany June 15, 2024
Health
Novo Nordisk faces stock market bloodbath after weight-loss drug trial disappoints
By Ryan Hogg and AFPDecember 20, 2024
Merck snags Chinese obesity drug in nearly $2 billion deal
Tech
Merck snags Chinese obesity drug in nearly $2 billion deal
By Robert Langreth and BloombergDecember 18, 2024
Novo Nordisk invests $1.2 billion in new Danish factory to expand beyond insulin and weight-loss
Tech
Novo Nordisk invests $1.2 billion in new Danish factory to expand beyond insulin and weight-loss
By AFPDecember 16, 2024
Close-up of a patient administering a dose of Zepbound (tirzepatide)
Health
Zepbound vs. Wegovy: New clinical trial says this weight-loss medication sheds more pounds
By Lindsey LeakeDecember 4, 2024
Biden proposes Medicare and Medicaid cover weight-loss drugs like Wegovy and Ozempic for millions of obese Americans
Health
Biden proposes Medicare and Medicaid cover weight-loss drugs like Wegovy and Ozempic for millions of obese Americans
By Amanda Seitz and The Associated PressNovember 26, 2024
High demand for weight loss drugs like Ozempic and Wegovy is impacting employer health care costs—but it can be critical for retaining talent
Leadership
High demand for weight loss drugs like Ozempic and Wegovy is impacting employer health care costs—but it can be critical for retaining talent
By Brit MorseNovember 21, 2024
1
  • 1
  • 2
  • 3
  • 4
  • 5
...7
Most Popular
Success
Palantir’s billionaire CEO says only two kinds of people will succeed in the AI era: trade workers—‘or you’re neurodivergent’placeholder alt text
By Preston ForeOctober 10, 2026
Success
Jeff Bezos says a 3-day workweek and more single-income households are on the way thanks to AI: ‘It’s going to be difficult to hire people’placeholder alt text
By Preston ForeOctober 9, 2026
Big Tech
Nvidia built a $5 trillion company while making employees pay for their own lunch—but they get far more lucrative perks like stock discountsplaceholder alt text
By Marco Quiroz-GutierrezOctober 10, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • TikTok icon
  • YouTube icon

    © 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
    FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.